Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bio-Techne Corp (TECH)

Bio-Techne Corp (TECH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Here's What to Expect From Bio-Techne's Next Earnings Report

Bio-Techne Corporation (TECH), headquartered in Minneapolis, Minnesota, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets. Valued at $10.1 billion by market cap, the company specializes in proteins, cytokines, growth factors, immunoassays and small molecules. The leading life sciences reagents and instruments company is expected to announce its fiscal second-quarter earnings for 2026 in the near term.

Ahead of the event, analysts expect TECH to report a profit of $0.34 per share on a diluted basis, down 2.9% from $0.35 per share in the year-ago quarter. The company has surpassed or met Wall Street’s...

Fundamentals

See More
  • Market Capitalization, $K 10,236,914
  • Shares Outstanding, K 155,813
  • Annual Sales, $ 1,220 M
  • Annual Income, $ 73,400 K
  • EBIT $ 110 M
  • EBITDA $ 220 M
  • 60-Month Beta 1.47
  • Price/Sales 8.39
  • Price/Cash Flow 26.42
  • Price/Book 5.12

Options Overview Details

View History
  • Implied Volatility 43.38% (-3.24%)
  • Historical Volatility 30.31%
  • IV Percentile 32%
  • IV Rank 26.94%
  • IV High 71.44% on 04/07/25
  • IV Low 33.04% on 02/21/25
  • Expected Move (DTE 4) 3.09 (4.71%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 1,032
  • Volume Avg (30-Day) 1,049
  • Put/Call OI Ratio 1.86
  • Today's Open Interest 26,856
  • Open Int (30-Day) 27,829
  • Expected Range 62.61 to 68.79

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.34
  • Number of Estimates 5
  • High Estimate 0.36
  • Low Estimate 0.32
  • Prior Year 0.35
  • Growth Rate Est. (year over year) -2.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
56.59 +16.10%
on 12/16/25
66.95 -1.87%
on 01/09/26
+6.88 (+11.70%)
since 12/09/25
3-Month
54.20 +21.22%
on 11/05/25
66.96 -1.88%
on 10/24/25
+5.80 (+9.68%)
since 10/09/25
52-Week
46.01 +42.80%
on 04/21/25
79.28 -17.13%
on 02/05/25
-9.49 (-12.62%)
since 01/08/25

Most Recent Stories

More News
Here's What to Expect From Bio-Techne's Next Earnings Report

Bio-Techne will release its second-quarter earnings soon, and analysts anticipate a single-digit profit dip.

TECH : 65.70 (+1.73%)
XLV : 157.31 (-0.51%)
$SPX : 6,966.28 (+0.65%)
3 Small-Cap Stocks We Keep Off Our Radar

3 Small-Cap Stocks We Keep Off Our Radar

FBIN : 58.14 (+5.71%)
TECH : 65.70 (+1.73%)
BBWI : 23.29 (+2.28%)
3 Reasons to Avoid TECH and 1 Stock to Buy Instead

3 Reasons to Avoid TECH and 1 Stock to Buy Instead

TECH : 65.70 (+1.73%)
1 S&P 500 Stock with Exciting Potential and 2 We Question

1 S&P 500 Stock with Exciting Potential and 2 We Question

TECH : 65.70 (+1.73%)
IFF : 69.10 (+0.76%)
AMGN : 326.10 (-1.21%)
Research Tools & Consumables Stocks Q3 Results: Benchmarking Bio-Techne (NASDAQ:TECH)

Research Tools & Consumables Stocks Q3 Results: Benchmarking Bio-Techne (NASDAQ:TECH)

TECH : 65.70 (+1.73%)
Bio-Techne to Present at the 2026 J.P. Morgan Healthcare Conference

MINNEAPOLIS , Dec. 23, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the 2026 J.P. Morgan Healthcare...

TECH : 65.70 (+1.73%)
3 of Wall Street’s Favorite Stocks That Concern Us

3 of Wall Street’s Favorite Stocks That Concern Us

TECH : 65.70 (+1.73%)
ACEL : 11.52 (-1.71%)
FNKO : 3.67 (-6.14%)
Bio-Techne Stock: Is TECH Underperforming the Healthcare Sector?

Despite Bio-Techne’s weak performance relative to the healthcare sector over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.

TECH : 65.70 (+1.73%)
XLV : 157.31 (-0.51%)
DGX : 174.44 (-1.86%)
Bio-Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial Biology

MINNEAPOLIS , Dec. 11, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced a strategic collaboration...

TECH : 65.70 (+1.73%)
Bio-Techne Launches the Enhanced Leoâ„¢ System Delivering Advanced Multiplexing and High-Throughput Protein Analysis

MINNEAPOLIS , Dec. 9, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the expanded launch and...

TECH : 65.70 (+1.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bio-Techne Corporation is a global life sciences company. It develops, manufactures, and sells biotechnology products and clinical diagnostic controls. It provides proteins, such as cytokines, growth factors, and enzymes; antibodies, including polyclonal and monoclonal antibodies; immunoassays comprising...

See More

Key Turning Points

3rd Resistance Point 68.79
2nd Resistance Point 67.87
1st Resistance Point 66.78
Last Price 65.70
1st Support Level 64.78
2nd Support Level 63.86
3rd Support Level 62.78

See More

52-Week High 79.28
Fibonacci 61.8% 66.57
Last Price 65.70
Fibonacci 50% 62.64
Fibonacci 38.2% 58.72
52-Week Low 46.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar